估值 33 亿美元的 Evolent Health 探索了 TPG、CD&R、KKR 和 Elevance Health 的潜在出售。 Evolent Health, valued at $3.3bn, explores potential sale with interest from TPG, CD&R, KKR, and Elevance Health.

价值33亿美元的医疗服务提供商Evolent Health正在考虑在私募股权公司TPG,CD&R和KKR以及健康保险公司Elevance Health的兴趣下进行潜在的销售. Healthcare services provider Evolent Health, valued at $3.3bn, is considering a potential sale following interest from private equity firms TPG, CD&R, and KKR, along with health insurer Elevance Health. Evolent 已经聘请了一名财务顾问，并已提交初步报价，但最终交易尚不确定。 Evolent has engaged a financial adviser, and initial bids have been submitted, though a final deal is not certain. 保密会谈正在进行中,预计将在今后几周内达成一项决议。 Confidential talks are ongoing, and a resolution may be expected in the coming weeks.